Bionano Genomics, Inc. (BNGO)

NASDAQ: BNGO · IEX Real-Time Price · USD
1.110
+0.020 (1.83%)
At close: Mar 28, 2024, 4:00 PM
1.120
+0.010 (0.90%)
After-hours: Mar 28, 2024, 7:56 PM EDT

Company Description

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.

It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.

The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.

In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing.

Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Bionano Genomics, Inc.
Bionano Genomics logo
Country United States
Founded 2003
IPO Date Aug 21, 2018
Industry Diagnostics & Research
Sector Healthcare
Employees 344
CEO Dr. Robert Erik Holmlin M.B.A., Ph.D.

Contact Details

Address:
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
United States
Phone (858) 888-7600
Website bionanogenomics.com

Stock Details

Ticker Symbol BNGO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001411690
CUSIP Number 09075F107
ISIN Number US09075F3055
Employer ID 26-1756290
SIC Code 3826

Key Executives

Name Position
Dr. Robert Erik Holmlin M.B.A., Ph.D. President, Chief Executive Officer, Secretary and Director
Mark Oldakowski Chief Operating Officer
Dr. Alka Chaubey FACMG, Ph.D. Chief Medical Officer
Gulsen Kama M.B.A. Chief Financial Officer
Mark Adamchak CPA Vice President of Accounting and Controller
Jonathan Dixon J.D. General Counsel
Stanislas Marin M.B.A., M.S. Vice President of Global Sales
Donna Polizio Global Head of Market Access
Cory Kreeck Global Head of People Operations
Dr. Klint Rose Ph.D. Head of Research and Development

Latest SEC Filings

Date Type Title
Mar 6, 2024 ARS Filing
Mar 5, 2024 10-K Annual Report
Mar 5, 2024 8-K Current Report
Feb 28, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 8, 2024 8-K Current Report
Nov 24, 2023 8-K Current Report
Nov 8, 2023 424B3 Prospectus
Nov 8, 2023 10-Q Quarterly Report
Nov 8, 2023 8-K Current Report